Hive Prospect Learning Center
Clinical trial cost, protocol, enrollment and biotech decision guides.
Plain-English answers that lead to free tools, not demo forms.
How Much Does a Phase 1 Clinical Trial Cost?There is no single honest Phase 1 price. The useful answer is a transparent budget built from protocol, site, patient, geography and vendor assumptions.Clinical Trial Cost Breakdown: What Actually Drives the Budget?A trial budget is a stack of patient, site, vendor, geography and time costs. The fastest way to understand it is to make every bucket explicit.Phase 1 in the U.S. vs Australia: How Should You Compare Cost?Do not compare countries as if each has one price. Compare actual capable sites, startup path, recruitment, incentives, logistics and evidence value.How to Choose a Country for a Clinical TrialCountry selection should optimize credible time-to-answer, not prestige, habit or a generic cost table.How Many Sites Does a Clinical Trial Need?More sites can increase recruitment capacity, but every site adds startup, monitoring and management burden. The answer depends on credible enrollment per site.How to Build a Clinical Trial Enrollment Forecast That Is Not FictionEnrollment forecasts fail when they multiply optimistic site estimates by the number of sites. Build the forecast from protocol-specific evidence.Clinical Trial Screen Failure: Why It Can Quietly Explode CostA high screen-failure rate means you must find and evaluate far more people than the enrollment target suggests.Patient Burden Is a Trial-Cost VariableTravel, caregiver needs, painful procedures and long visits affect recruitment, retention and the number of sites you may need.How Protocol Complexity Drives Clinical Trial CostComplexity is expensive when it creates visits, procedures, vendors, site burden and data that do not change a decision.How to Spot Clinical Trial Protocol Amendment Risk Before StartupAmendments become expensive after sites open. The best time to pressure-test complexity is before the study network is committed.Clinical Trial Site Feasibility: Questions That Actually MatterThe best feasibility questions test whether a site can execute this exact protocol and enroll this exact population.Clinical Trial Site Startup Time: What Slows It Down?Startup delay is usually a chain of contracts, budgets, regulatory/ethics work, pharmacy, training and vendor dependencies rather than one single clock.CRO Cost Breakdown: What Are You Actually Paying For?A CRO proposal is a bundle of work. Unbundle it enough to understand which tasks buy evidence and which are coordination overhead.How to Compare CRO Proposals Apples-to-ApplesDo not compare bottom-line totals until you normalize assumptions, units, pass-throughs, exclusions and escalation rules.Cost-to-Truth: A Better Way to Think About Clinical Development SpendCost-to-Truth asks how much time and money are required to obtain the next credible answer that changes a management decision.How to Prioritize Indications in Early Biotech DevelopmentThe biggest market is not always the best first indication. Early development often benefits from the population that gives the cleanest human proof.Biotech Licensing Diligence: What to Check Before Spending Months on a DealResolve whether the asset is actionable before building an elaborate valuation.How to Evaluate a Stranded or Discontinued Biotech AssetA discontinued program can reflect biology, financing, strategy, execution or corporate events. Classify the reason before classifying the asset.What Should a First-in-Human Trial Prove Besides Safety?A first-in-human study can be designed to create strategic evidence, not merely complete a conventional Phase 1 checklist.Does Every Procedure in Your Clinical Trial Protocol Earn Its Keep?Every procedure should protect safety, support the primary evidence objective, or change a defined decision.Why Clinical Trial Budgets OverrunOverruns usually come from assumptions that were wrong, scope that was incomplete, or complexity that became expensive after startup.